Awwad M, North R J
Trudeau Institute, Saranac Lake, New York 12983.
Cancer Res. 1990 Apr 15;50(8):2228-33.
This study shows that it is not possible to cause regression of the immunogenic SA-1 sarcoma by adoptive immunotherapy with tumor-sensitized T-cells, unless the tumor-bearing recipient is exposed to a sublethal dose of gamma-irradiation to remove a barrier that prevents adoptive immunity from being expressed. This barrier to adoptive immunotherapy was found to be regenerated between 2 and 4 weeks following irradiation, and its regeneration was associated with general repopulation of host T-cells. However, it was not regenerated in the absence of the thymus, thus showing that it is T-cell dependent. Evidence that it is caused by the presence of CD4+ suppressor T-cells was shown by the finding that it can be removed by depleting mice of CD4+ T-cells with anti-L3T4 monoclonal antibodies, but not by depleting them of CD8+ T-cells with anti-Lyt-2 monoclonal antibodies. Again, the barrier could be restored to irradiated recipients by infusing them with CD4+ T-cells, but not with CD8+ T-cells, from tumor-bearing donors. The barrier to adoptive immunotherapy was found to be tumor induced and to be paradoxically generated in concert with host concomitant immunity.
本研究表明,采用肿瘤致敏T细胞进行过继性免疫治疗不可能使免疫原性SA - 1肉瘤消退,除非荷瘤受体接受亚致死剂量的γ射线照射以消除阻止过继性免疫表达的屏障。发现这种过继性免疫治疗的屏障在照射后2至4周之间再生,其再生与宿主T细胞的总体再增殖有关。然而,在无胸腺的情况下它不会再生,因此表明它是T细胞依赖性的。有证据表明它是由CD4 +抑制性T细胞的存在引起的,这一发现表明,用抗L3T4单克隆抗体耗尽小鼠的CD4 + T细胞可消除该屏障,但用抗Lyt - 2单克隆抗体耗尽CD8 + T细胞则不能。同样,通过向受照射的受体输注来自荷瘤供体的CD4 + T细胞,而不是CD8 + T细胞,可使该屏障恢复。发现过继性免疫治疗的屏障是肿瘤诱导的,并且与宿主伴随免疫协同产生,这很矛盾。